These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 26029165)

  • 1. Preclinical Effectiveness of Selective Inhibitor of IRS-1/2 NT157 in Osteosarcoma Cell Lines.
    Garofalo C; Capristo M; Mancarella C; Reunevi H; Picci P; Scotlandi K
    Front Endocrinol (Lausanne); 2015; 6():74. PubMed ID: 26029165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insulin Receptor Substrate Suppression by the Tyrphostin NT157 Inhibits Responses to Insulin-Like Growth Factor-I and Insulin in Breast Cancer Cells.
    Yang Y; Chan JY; Temiz NA; Yee D
    Horm Cancer; 2018 Dec; 9(6):371-382. PubMed ID: 30229539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting IRS-1/2 in Uveal Melanoma Inhibits In Vitro Cell Growth, Survival and Migration, and In Vivo Tumor Growth.
    Chattopadhyay C; Bhattacharya R; Roszik J; Khan FS; Wells GA; Villanueva H; Qin Y; Bhattacharya R; Patel SP; Grimm EA
    Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway.
    Niu NK; Wang ZL; Pan ST; Ding HQ; Au GH; He ZX; Zhou ZW; Xiao G; Yang YX; Zhang X; Yang T; Chen XW; Qiu JX; Zhou SF
    Drug Des Devel Ther; 2015; 9():1555-84. PubMed ID: 25792811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NVP-BEZ235 as a new therapeutic option for sarcomas.
    Manara MC; Nicoletti G; Zambelli D; Ventura S; Guerzoni C; Landuzzi L; Lollini PL; Maira SM; García-Echeverría C; Mercuri M; Picci P; Scotlandi K
    Clin Cancer Res; 2010 Jan; 16(2):530-40. PubMed ID: 20068094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensitivity of breast cancer cell lines to the novel insulin-like growth factor-1 receptor (IGF-1R) inhibitor NVP-AEW541 is dependent on the level of IRS-1 expression.
    Mukohara T; Shimada H; Ogasawara N; Wanikawa R; Shimomura M; Nakatsura T; Ishii G; Park JO; Jänne PA; Saijo N; Minami H
    Cancer Lett; 2009 Sep; 282(1):14-24. PubMed ID: 19345478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia.
    Chiarini F; Grimaldi C; Ricci F; Tazzari PL; Evangelisti C; Ognibene A; Battistelli M; Falcieri E; Melchionda F; Pession A; Pagliaro P; McCubrey JA; Martelli AM
    Cancer Res; 2010 Oct; 70(20):8097-107. PubMed ID: 20876803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of the Anticancer Drug NT157 on Tyrosine Kinase Signaling Networks.
    Su SP; Flashner-Abramson E; Klein S; Gal M; Lee RS; Wu J; Levitzki A; Daly RJ
    Mol Cancer Ther; 2018 May; 17(5):931-942. PubMed ID: 29440449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retinoic acid-induced growth arrest of MCF-7 cells involves the selective regulation of the IRS-1/PI 3-kinase/AKT pathway.
    del Rincón SV; Rousseau C; Samanta R; Miller WH
    Oncogene; 2003 May; 22(22):3353-60. PubMed ID: 12776186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NT157 exhibits antineoplastic effects by targeting IRS and STAT3/5 signaling in multiple myeloma.
    de Queiroz GN; Lima K; de Miranda LBL; Rego EM; Traina F; Machado-Neto JA
    Hematol Transfus Cell Ther; 2024 Mar; ():. PubMed ID: 38523043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The novel synthesized 6-fluoro-(3-fluorophenyl)-4-(3-methoxyanilino)quinazoline (LJJ-10) compound exhibits anti-metastatic effects in human osteosarcoma U-2 OS cells through targeting insulin-like growth factor-I receptor.
    Chen KT; Hour MJ; Tsai SC; Chung JG; Kuo SC; Lu CC; Chiu YJ; Chuang YH; Yang JS
    Int J Oncol; 2011 Sep; 39(3):611-9. PubMed ID: 21667022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of insulin-like growth factor signaling pathways in mammary gland by pure antiestrogen ICI 182,780.
    Chan TW; Pollak M; Huynh H
    Clin Cancer Res; 2001 Aug; 7(8):2545-54. PubMed ID: 11489838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tamoxifen interferes with the insulin-like growth factor I receptor (IGF-IR) signaling pathway in breast cancer cells.
    Guvakova MA; Surmacz E
    Cancer Res; 1997 Jul; 57(13):2606-10. PubMed ID: 9205064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progesterone receptor-B regulation of insulin-like growth factor-stimulated cell migration in breast cancer cells via insulin receptor substrate-2.
    Ibrahim YH; Byron SA; Cui X; Lee AV; Yee D
    Mol Cancer Res; 2008 Sep; 6(9):1491-8. PubMed ID: 18819936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simultaneous perturbation of the MAPK and the PI3K/mTOR pathways does not lead to increased radiosensitization.
    Kuger S; Flentje M; Djuzenova CS
    Radiat Oncol; 2015 Oct; 10():214. PubMed ID: 26498922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IGF-1R inhibitor PQ401 inhibits osteosarcoma cell proliferation, migration and colony formation.
    Qi B; Zhang R; Sun R; Guo M; Zhang M; Wei G; Zhang L; Yu S; Huang H
    Int J Clin Exp Pathol; 2019; 12(5):1589-1598. PubMed ID: 31933976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma.
    Baumann P; Mandl-Weber S; Oduncu F; Schmidmaier R
    Exp Cell Res; 2009 Feb; 315(3):485-97. PubMed ID: 19071109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors.
    Scotlandi K; Manara MC; Nicoletti G; Lollini PL; Lukas S; Benini S; Croci S; Perdichizzi S; Zambelli D; Serra M; García-Echeverría C; Hofmann F; Picci P
    Cancer Res; 2005 May; 65(9):3868-76. PubMed ID: 15867386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors.
    Buck E; Eyzaguirre A; Rosenfeld-Franklin M; Thomson S; Mulvihill M; Barr S; Brown E; O'Connor M; Yao Y; Pachter J; Miglarese M; Epstein D; Iwata KK; Haley JD; Gibson NW; Ji QS
    Cancer Res; 2008 Oct; 68(20):8322-32. PubMed ID: 18922904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for Gefitinib ('Iressa') response and resistance.
    Knowlden JM; Jones HE; Barrow D; Gee JM; Nicholson RI; Hutcheson IR
    Breast Cancer Res Treat; 2008 Sep; 111(1):79-91. PubMed ID: 17902048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.